Company MYND Life Sciences Inc.

Equities

MYND

CA62857B1094

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Market Closed - Canadian Securities Exchange Other stock markets 09:30:00 2024-04-22 am EDT			5-day change	1st Jan Change
0.03 ^CAD	0.00%		0.00%	-25.00%

Mar. 21	MYND Life Sciences Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
Mar. 04	MYND Life Sciences Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	CI

MYND Life Sciences Inc. is a Canada-based medical biotech drug research and development company. The Company is focused on neuro-pharmaceutical drug development, diagnostics and vaccines. It is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio) pharmaceutical companies by molecular concepts for the applications of psilocybin analogs for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property. The Company is engaged in collaborative research with the Michael Smith Laboratories at the University of British Columbia.

Managers	Title	Age	Since
John Campbell CEO	Chief Executive Officer	53	20-11-25
Lyle Oberg FOU	Founder	63	18-07-05
Wilfred A. Jefferies FOU	Founder	65	18-07-05
Lih-Ming Tam DFI	Director of Finance/CFO	-	-
Chaahat S. B. Singh COO	Chief Operating Officer	-	22-03-08
Iryna Saranchova CTO	Chief Tech/Sci/R&D Officer	-	21-05-14

Members of the board	Title	Age	Since
Wilfred A. Jefferies FOU	Founder	65	18-07-05
Lyle Oberg FOU	Founder	63	18-07-05
John Campbell CEO	Chief Executive Officer	53	20-11-25
Roslyn Ritchie-Derrien BRD	Director/Board Member	61	20-11-25
Scott L. Nicoll BRD	Director/Board Member	-	21-10-27

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	24,358,625	9,785,852 ( 40.17 %)	0	40.17 %

Name	Equities	%	Valuation
Wilfred A. Jefferies 21.63 %	10,340,583	21.63 %	217 152 $
Lyle Oberg 6.151 %	2,941,320	6.151 %	61 768 $
Roslyn Ritchie-Derrien 2.595 %	1,240,870	2.595 %	26 058 $
John Campbell 0.1046 %	50,000	0.1046 %	1 050 $
Scott L. Nicoll 0.000000 %	0	0.000000 %	- $
Greenlight Innovation Partners 0.000000 %	0	0.000000 %	- $

MYND Life Sciences, Inc.

719 Finns Road

V1X 5B7, Kelowna

http://www.myndsciences.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MYND LIFE SCIENCES INC.	-25.00%	1.05M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs